康莱特注射液辅助治疗中晚期非小细胞肺癌的效果观察  被引量:4

A Clinical Study on Kanglaite injection combined with comprehensive therapy in the treatment of patients with advanced non-small cell lung cancer

在线阅读下载全文

作  者:魏卫[1] 袁保兰[1] 吴海江[1] 戴秀梅[1] 罗伟[1] 李桂金[1] 杨静[2] 

机构地区:[1]江苏省徐州市中心医院东南大学附属徐州医院肿瘤科,221009 [2]徐州市中医院南京中医药大学附属徐州医院肿瘤科

出  处:《中国综合临床》2012年第12期1236-1239,共4页Clinical Medicine of China

基  金:江苏省卫生厅医学科技发展基金会课题(P200941)

摘  要:目的观察康莱特注射液辅助治疗中晚期非小细胞肺癌的临床效果。方法将61例晚期非小细胞肺癌患者随机分为治疗组31例和对照组30例,两组均给予综合治疗,治疗组在此基础上加用康莱特注射液200ml静脉滴注,观察两组生活质量疗效、疼痛缓解情况、临床疗效和不良反应等情况。结果(1)生活质量疗效:治疗组改善20例(64.5%),稳定8例(25.8%),下降3例(9.7%);对照组分别为9例(30.O%),9例(30.O%),12例(40.0%),治疗组优于对照组(U=2.91,P〈0.01)。(2)疼痛缓解情况:治疗组完全缓解、部分缓解、无变化、进展者分别为5例(16.1%),16例(51.6%),6例(19.4%),4例(12.9%);对照组分别为2例(6.7%),9例(30.0%),11例(36.7%),8例(26.7%),治疗组优于对照组(U=2.32,P〈0.05)。(3)临床疗效:治疗组部分缓解、稳定、进展者分别为12例(38.7%),14例(45.2%),5例(16.1%),对照组分别为8例(26.7%),8例(26.7%),14例(46.7%),治疗组优于对照组(U=2.04,P〈0.05)。(4)不良反应:治疗组白细胞计数和胃肠道反应Ⅲ、Ⅳ度发生率分别为22.6%(7/31)和19.4%(6/31),而对照组分别为53.3%(16/30)和46.7%(14/30),差异均有统计学意义(x2值分别为6.139和5.161,P均〈0.05)。结论康莱特注射液联合治疗可提高晚期非小细胞肺癌临床疗效,减轻不良反应,保护免疫功能,提高患者生存质量。Objective To study the effect of Kanglaite combined with comprehensive therapy on advanced non-small cell lung cancer. Methods Sixty-one patients wiEh advanced non-small cell lung cancer were randomly divided into treatment group ( n = 31 ) and control group ( n = 30 ) . Both groups were given comprehensive therapy. Treatment group were additionally treated with intravenous injection of 200 ml Kanglaite. Clinical efficacy, quality of life, pain relief and adverse reactions of the two groups were observed. Results ( 1 ) Quality of life was improved in 20 cases ( 64. 5% ) , stabled in 8 cases ( 25.8% ) , declined in 3 cases ( 9.7% ) of treatment group, and in the control group there w^re 9 eases ( 30. 0% )improved,9 cases (30.0%) stabilized, 12 cases (40. 0% ) declined respectively. Quality of life in treatment group was higher than in control group ( U = 2. 91, P 〈 0. 01 ). ( 2 ) Pain relief: the number of patients with complete remission, partial remission, no change, and progression were 5 cases ( 16. 1% ), 16 cases (51.6% ), 16 cases(51.6% ),6 cases(19.4% ) and 4 cases( 12. 9% ) in treatment group,and in control group they were 2 cases (6. 7% ) ,9 cases (30. 0% ), 11 cases (36. 7% ) and 8 cases (26. 7 % ) respectively. The effect of treatment on pain relief in treatment group was better than that in control group ( U = 2. 32, P 〈 0. 05 ). ( 3 ) Clinical efficacy: in the treatment group there were 12 cases ( 38.7% ) with partial remission, 14 cases ( 45.2% ) stabilized,and 5 cases (16. 1% ) progressed,and in control group the numbers were 8 cases (26. 7% ) ,8 cases (26.7%) and 14 cases (46.7%) respectively. The clinical efficacy in treatment group was better than that in the control group( U = 2. 04 ,P 〈 0. 05). (4) There were significant difference on the change of white blood cell count and gastrointestinal reactions llI and 1V degrees between treatment group and contrl group[ 22. 6

关 键 词:非小细胞肺癌 康莱特注射液 T细胞亚群 生存质量 

分 类 号:R734.2[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象